Market Size
Global Artificial Blood Market reached US$ 4,444.3 million in 2025 and is expected to reach US$ 8,648.0 million by 2033, growing at a CAGR of 8.7% during the forecast period 2026-2033.
While true blood performs different functions, artificial blood is designed to transport oxygen and carbon dioxide through the body. Based on the type of artificial blood it can be produced in different ways including synthetic production, chemical isolation, or recombinant biochemical technology.
The advantages of artificial blood include providing critical benefits over allogenic blood transfusions by delivering increased oxygen-carrying capacity, saving time in trauma cases and battlefield scenarios, higher life than regular blood, minor chances of the disease spreading, and the ability to manufacture larger quantities of blood. Artificial blood is available in the market in terms of hemoglobin-based oxygen carriers and perfluorocarbon emulsions.
Market Scope
| Metrics | Details |
| CAGR | 8.7% |
| Market Size Available for Years | 2023-2033 |
| Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product Type, Source, Process, Application, End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
The artificial blood market is gaining significant momentum driven by the increasing global shortage of donor blood and the rising demand for safe and readily available blood substitutes in emergency and critical care settings. Growing incidences of trauma, surgical procedures, and chronic conditions such as anemia are accelerating the need for artificial oxygen carriers that can function without compatibility constraints. Continuous advancements in biotechnology, including hemoglobin-based oxygen carriers, perfluorocarbon emulsions, and stem cell-derived blood products, are improving safety, efficiency, and shelf life. Increasing investments in research and development, along with expanding clinical trials and innovations such as lab-grown red blood cells and universal blood substitutes, are further supporting market growth and acceptance across healthcare systems.
However, the market faces significant challenges, including high research and development costs, complex regulatory approval processes, and concerns related to safety, toxicity, and long-term efficacy of artificial blood products. Technical limitations in fully replicating the complex functions of natural blood and potential side effects continue to hinder widespread commercialization. Additionally, high production costs and price sensitivity in emerging markets can restrict adoption. Despite these challenges, strong opportunities exist with increasing demand in emergency medicine, military healthcare, and remote or resource-limited settings where traditional blood supply is limited. Ongoing innovation in next-generation oxygen carriers, nanotechnology-based solutions, and extended shelf-life products is expected to unlock new growth potential, even as regulatory, clinical, and technological challenges continue to shape the market landscape.
Adverse effects of artificial blood
Adverse effects of hemoglobin-based oxygen carriers include hypertension, abdominal pain, skin rash, diarrhea, jaundice, hemoglobinuria, oliguria, fever, stroke, and laboratory abnormalities such as an increase in lipase. These adverse reactions could reduce the adoption of artificial blood in surgical procedures and for transfusions.
Market Segment Analysis
The global artificial blood market is segmented based on product type, source, process, application, end-user, and region.
Hemoglobin-based oxygen carriers segment is expected to dominate the market share
Hemoglobin-based oxygen carriers segment is expected to hold a significant position in the market share due to a variety of factors. HBOCs have been developed to efficiently transport and release oxygen, which is comparable to the function of natural hemoglobin in red blood cells. This makes them extremely effective for oxygen delivery, especially in situations of emergency.
HBOCs can be employed in a variety of medical settings, including operations, injuries, and anemia therapies. Their ability to adapt improves their commercial potential across numerous applications. Significant R&D investment is being made to improve the efficacy and safety features of HBOCs, resulting in advances that can increase their adoption in clinical settings. Thus, the above factors are expected to hold a significant position in the market share.
Market Geographical Share
North America is expected to hold a significant position in the artificial blood market share
North America dominates the global artificial blood market during the forecast period owing to the rise in trauma deaths due to excessive blood loss before admission, and an increase in the prevalence of anemia and blood-related disorders across the region leading to the development of novel artificial blood.
The rising studies in the development of artificial blood in the region to substitute the original human blood and use it for the transfusion processes in the anemic and other patients are expected to drive market growth in the region.
For instance, according to a publication by UMSOM, UMSOM will manage the $46.4 million four-year research project administered by the Defense Advanced Research Projects Agency (DARPA), in collaboration with the University of Maryland School of Pharmacy (UMSOP) and more than a dozen universities and biotech companies. A Physician-scientist of UMSOM will head the new federally-funded research program to develop and test a whole blood product, storable at room temperature, that can be used to transfuse wounded soldiers in the field within 30 minutes of injury, potentially saving thousands of lives
Recent Developments
February 2026: Across North America, Europe, and Asia Pacific, increasing demand for blood substitutes in trauma care, surgeries, and emergency medicine significantly accelerated growth in the artificial blood market, driven by global blood shortages and rising need for universal transfusion solutions.
January 2026: Advancements in hemoglobin-based oxygen carriers (HBOCs), perfluorocarbon emulsions, and stem cell-derived blood components enabled improved oxygen delivery, longer shelf life, and enhanced safety in artificial blood products.
December 2025: Leading companies such as Hemarina, KaloCyte Inc., NuvOx Pharma, Prolong Pharmaceuticals, Terumo Corporation, and Grifols S.A. expanded artificial blood pipelines and focused on commercialization of next-generation oxygen therapeutics.
November 2025: Increasing clinical trials and research initiatives in synthetic and lab-grown blood, including universal artificial blood compatible with all blood types, accelerated innovation and potential large-scale adoption.
October 2025: Growing integration of nanotechnology, synthetic biology, and bioengineering techniques improved stability, biocompatibility, and scalability of artificial blood products.
September 2025: In the United States and Europe, strong investments in biotechnology research, defense-funded programs, and advanced healthcare infrastructure significantly supported market expansion.
August 2025: In China, India, Japan, and South Korea, increasing healthcare expenditure, rising trauma cases, and government support for advanced medical technologies accelerated regional market growth.
July 2025: Continuous innovation in synthetic oxygen carriers, nano-encapsulated hemoglobin, and long-storage blood substitutes, along with increasing collaborations between biotech companies and research institutions, supported long-term global growth of the artificial blood market.
Market Competitive Landscape
The major global players in the market include Hemarina, KaloCyte, Inc., SpheriTech Limited, and Hemoglobin Oxygen Therapeutics LLC among others.
Market Segmentation
By Product Type
- Hemoglobin-based Oxygen Carriers
- Perfluorocarbon Emulsion
By Source
- Human Hemoglobin
- Animal Hemoglobin
- Stem Cells
- Synthetic Polymers
- Microorganisms
- Others
By Process
- Synthetic Production
- Chemical Isolation
- Recombinant Biochemical Technology
By Application
- Anemia
- Organ Transplantation
- Injuries & Trauma
- Cardiovascular Diseases
- Maternal Conditions
- Others
By End-User
- Hospitals
- Clinics
- Blood Banks
- Research Institutes
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Why Purchase the Report?
- To visualize the global artificial blood market segmentation based on product type, source, process, application, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of artificial blood market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global artificial blood market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
